CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Takeda Pharmaceuticals U.S.A., Inc. v. Mylan Pharmaceuticals Inc.

1:19-cv-02216

Overview

Case Number 1:19-cv-02216
Filing Date 2019-12-02
Status Terminated
Termination Date 2025-04-17
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand Plaintiff

Parties

Intervenor

Par Pharmaceutical Inc. Operating Company

Represented By

1 Attorneys Listed

Karen Elizabeth Keller

Shaw Keller LLP

Tel: +1 (302) 298-0700

1105 North Market Street, 12th Floor, Wilmington, DE 19801

Counter Claimant

Mylan Pharmaceuticals Inc. Operating Company

Represented By

8 Attorneys Listed

Elham F. Steiner

Email: esteiner@wsgr.com

Cortlan S. Hitch

Morris James LLP

Tel: +1 (302) 888-6988
Fax: +1 (302) 571-1750

3205 Avenue North Boulevard, Suite 100

Shyamkrishna Palaiyanur

UNDELIVERABLE EMAIL 7/31/2020

Sheryl S. Bassin

Email: sbassin@wsgr.com

Nicole W. Stafford

Email: nstafford@wsgr.com

Kenneth Laurence Dorsney

Morris James LLP

Tel: +1 (302) 888-6855

3205 Avenue North Boulevard, Suite 100

Jessica L. Margolis

Email: jmargolis@wsgr.com

David S. Steuer

Email: dsteuer@wsgr.com

Counter Defendant

Takeda Pharmaceuticals U.S.A., Inc. Operating Company

Represented By

8 Attorneys Listed

Alan Richard Silverstein

Connolly Gallagher LLP

Tel: +1 (302) 757-7322

1201 N. Market St., 20th Floor

Jonathan Herstoff

Email: jherstoff@haugpartners.com

Camile Y. Turner

Email: cturner@haugpartners.com

Thatcher A. Rahmeier

Faegre Drinker Biddle & Reath LLP

Tel: +1 (302) 467-4211
Fax: +1 (302) 467-4201

222 Delaware Avenue, Suite 1410

Porter F. Fleming

Email: pfleming@haugpartners.com

Nicholas F. Giove

Email: ngiove@haugpartners.com

Edgar H. Haug

Email: ehaug@haugpartners.com

Francis DiGiovanni

Faegre Drinker Biddle & Reath LLP

Tel: +1 (302) 467-4266
Fax: +1 (302) 467-4201

222 Delaware Avenue, Suite 1410

Third Party Defendant

Hikma Pharmaceuticals International Limited NPE (University / Research)

Represented By

1 Attorneys Listed

Dominick T. Gattuso

Heyman Enerio Gattuso & Hirzel LLP

Tel: +1 (302) 472-7300

222 Delaware Avenue, Suite 900

Hikma Pharmaceuticals USA Inc. Operating Company

Represented By

1 Attorneys Listed

Dominick T. Gattuso

Heyman Enerio Gattuso & Hirzel LLP

Tel: +1 (302) 472-7300

222 Delaware Avenue, Suite 900

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 4 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts 5 proceedings
🏛️
USPTO PTAB Trials Counterparts in force
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (4): 🇺🇸 US
Parallel Proceedings Across Jurisdictions (5 found):
U.S. Courts: 5
U.S. District Court 2023-11-06
1:23-cv-01264

Takeda Pharmaceuticals U.S.A., Inc. v. Scilex Pharmaceuticals Inc.

U.S. Family Sibling (["US7619004", "US7820681", "US7964648", "US8093297", "US8097655", "US8440722"])
Status: DED
U.S. District Court 2016-10-24
1:16-cv-00987

Takeda Pharmaceuticals U.S.A., Inc. v. Mylan Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2014-02-27
1:14-cv-00268

Takeda Pharmaceuticals USA Inc. v. Watson Laboratories Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-08-30
1:13-cv-01524

Takeda Pharmaceuticals USA Inc. v. Par Pharmaceutical Companies Inc.

Asserted Patent
Status: DED
U.S. District Court 2012-04-04
1:12-cv-00419

Takeda Pharmaceuticals U.S.A. Inc. v. Par Pharmaceutical Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

17 Patents

There are 17 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US7906519
Methods for concomitant administration of colchicine and a second active agent
Filed: 2010-08-18
Issued: 2011-03-15
Active (3.7 yrs remaining)
Expires: 2030-08-18
US7935731
Methods for concomitant administration of colchicine and macrolide antibiotics
Filed: 2010-05-25
Issued: 2011-05-03
Active (3.5 yrs remaining)
Expires: 2030-05-25
US8093298
Methods for concomitant administration of colchicine and macrolide antibiotics
Filed: 2011-05-18
Issued: 2012-01-10
Active (4.5 yrs remaining)
Expires: 2031-05-18
US7964648
Methods for concomitant administration of colchicine and a second active agent
Filed: 2010-01-15
Issued: 2011-06-21
Active (3.2 yrs remaining)
Expires: 2030-01-15
US8093297
Methods for concomitant administration of colchicine and a second active agent
Filed: 2011-04-22
Issued: 2012-01-10
Active (4.4 yrs remaining)
Expires: 2031-04-22

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Active Threat

Active Threat — Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

115

Dispositive

92

Granted

10

Denied

2

Pending / Review

77

Motions by Category

Motion for Preliminary Injunction / TRO 31 Procedural / Extension Motion 14 Motion to Dismiss 31 Motion to Dismiss (FRCP 12(b)(6)) 1 Claim Construction / Markman Filing 1 Motion for Summary Judgment (Rule 56) 29 Motion to Compel Discovery 1 Motion to Strike / Sanctions 7

Key Dispositive Motions & Rulings

Motion for Summary Judgment (Rule 56) Pending / Under Review
REQUEST for Oral Argument by Mylan Pharmaceuticals Inc. re 383 MOTION for Summary Judgment of No Damages. (Dorsney, Kenneth) (Entered: 03/12/2025)
Entry #424 • 2025-03-12 Document →
Motion for Summary Judgment (Rule 56) Pending / Under Review
REPLY BRIEF re 383 MOTION for Summary Judgment of No Damages filed by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) (Entered: 03/07/2025)
Entry #421 • 2025-03-07 Document →
Motion for Summary Judgment (Rule 56) Pending / Under Review
REQUEST for Oral Argument by Takeda Pharmaceuticals U.S.A., Inc. re 383 MOTION for Summary Judgment of No Damages. (DiGiovanni, Francis) (Entered: 03/07/2025)
Entry #422 • 2025-03-07 Document →
Motion for Summary Judgment (Rule 56) Pending / Under Review
[SEALED] ANSWERING BRIEF in Opposition re 383 MOTION for Summary Judgment of No Damages filed by Mylan Pharmaceuticals Inc..Reply Brief due date per Local Rules...
Entry #406 • 2025-02-21 Document →
Motion for Summary Judgment (Rule 56) Pending / Under Review
SO ORDERED Granting 404 Stipulation and Proposed Order Regarding Motion for Summary Judgment on Damages (*Reset Briefing Schedule: re 383 MOTION for Summary Jud...
Entry #405 • 2025-02-05 Document →
Motion for Summary Judgment (Rule 56) Pending / Under Review
MOTION for Summary Judgment of No Damages - filed by Takeda Pharmaceuticals U.S.A., Inc.. (DiGiovanni, Francis) Modified on 1/24/2025 (nms). (Entered: 01/24/202...
Entry #383 • 2025-01-24 Document →

Docket Entries

(770 total)

Expedited Motion For Confidential Treatment of Certain Filings - filed by Takeda Pharmaceuticals U.S.A., Inc. - filed by Takeda Pharmaceuticals U.S.A., Inc. (Attachments: # 1 Civil Cover Sheet)(rwc) Modified on 12/4/2019 (nms). (Entered: 12/02/2019)

Entry #1 • 2019-12-02
1

Expedited Motion For Confidential Treatment of Certain Filings - filed by Takeda Pharmaceuticals U.S.A., Inc. - filed by Takeda Pharmaceuticals U.S.A., Inc. (Attachments: # 1 Civil Cover Sheet)(rwc) Modified on 12/4/2019 (nms). (Entered: 12/02/2019)

Entry #1 • 2019-12-02
2
Pleading / Complaint

[SEALED] COMPLAINT - filed with Jury Demand against Mylan Pharmaceuticals Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 032729.) - filed by Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z)(rwc) (Attachment 22 replaced on 12/3/2019) (rwc). (Attachment 23 replaced on 12/3/2019) (rwc). (Main Document 2 replaced on 12/10/2019) (nms). (Entered: 12/03/2019)

Entry #2 • 2019-12-02
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) - (SEE ATTACHED LIST). (rwc) (Entered: 12/03/2019)

Entry #3 • 2019-12-02
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Takeda Pharmaceutical Company Limited, Corporate Parent Takeda Pharmaceuticals International AG for Takeda Pharmaceuticals U.S.A., Inc. filed by Takeda Pharmaceuticals U.S.A., Inc. (rwc) (Entered: 12/03/2019)

Entry #4 • 2019-12-02
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc